hypocalcemia
HYPOCALCEMIA
Hypocalcemia is the occurs when serum calcium concentration is below the lower limit of normal range.
Acute hypocalcemia has neuromuscular tetany as hallmark symptom. Patients have rapid decrease in serum calcium and present with symptomatic hypocalcemia.
It is an emergency condition and requires immediate attention. Ca (IV) should be administered until signs and symptoms abate or until serum Ca levels rise.
Chronic hypocalcemia has asymptomatic mild hypocalcemia. Treatment is necessary to avoid long term complications. Oral Ca may be administered.
Drug Information

Indication: Correction of combined vit D & Ca deficiency in the elderly. As adjunct to treatment of osteoporosis in pa...

Indication: Prevention & treatment of Ca deficiency.

Indication: Treatment & prevention of vit D deficiency. Adjunctive treatment for osteoporosis. Reduces risk of falling...

Calcium with Vitamin D Plus YSP
calcium carbonate + vitamin D

Indication: Dietary supplement.

Calcium with Vitamin D YSP
calcium + vitamin D3

Indication: Prevention of Ca deficiency.

Calcium-D-Redoxon
ascorbic acid + calcium + colecalciferol + pyridox...

Indication: Health supplement.

Cebion Vitamin C + Calcium
ascorbic acid + calcium carbonate

Indication: Dietary supplement.

Indication: Pregnancy & lactation. Treatment & prevention of postmenopausal osteoporosis. Prevention of osteoporos...

1  /  3
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Among patients with rheumatoid arthritis, those who are obese are more likely to have worse disease activity, lower functional ability and poorer health-related quality of life compared with their nonobese counterparts, a study has found.
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Stephen Padilla, 13 Apr 2018
The use of dipeptidyl peptidase-4 inhibitors may heighten the risk of inflammatory bowel disease (IBD) in patients with type 2 diabetes (T2D), according to a recent study.